Encore Dermatology to Acquire US Commercialization Rights for Dr. Reddy’s Three Dermatology Products

 Encore Dermatology to Acquire US Commercialization Rights for Dr. Reddy’s Three Dermatology Products

Encore Dermatology to Acquire US Commercialization Rights for Dr. Reddy’s Three Dermatology Products

Shots:

  • Encore through its subsidiary Promius Pharma, has acquired US commercialization rights for Sernivo spray (betamethasone dipropionate), Trianex (Triamcinolone Acetonide Ointment, USP) and Promiseb from Dr. Reddy
  • The focus of the acquisition is to expand Encore’s portfolio of dermatology products for the treatment of skin diseases such as psoriasis, atopic dermatitis and acne
  • Sernivo (betamethasone dipropionate) spray 0.05% is targeted to reduce the symptoms of mild-to-moderate plaque psoriasis, such as itching, flaking & redness. Trianex 0.005% is a corticosteroid ointment used to relief inflammatory and itching symptoms of corticosteroid-responsive skin diseases

Click here to read full press release/ article | Ref: Business Wire | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post